Celldex Therapeutics (CLDX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
7.0M
Operating Income
-195.1M
-2,778.89%
Net Income
-157.9M
-2,248.76%
EPS (Diluted)
-$2.45
Balance Sheet Metrics
Total Assets
792.3M
Total Liabilities
45.3M
Shareholders Equity
747.0M
Debt to Equity
0.06
Cash Flow Metrics
Operating Cash Flow
-133.8M
Free Cash Flow
-159.7M
Revenue & Profitability Trend
Celldex Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 7.0M | 6.9M | 2.4M | 4.7M | 7.4M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 202.1M | 148.9M | 109.5M | 73.8M | 57.0M |
| Operating Income | -195.1M | -142.0M | -107.1M | -69.1M | -49.6M |
| Pre-tax Income | -157.9M | -141.4M | -112.3M | -70.7M | -60.9M |
| Income Tax | - | 0 | 0 | -227.0K | -1.2M |
| Net Income | -157.9M | -141.4M | -112.3M | -70.5M | -59.8M |
| EPS (Diluted) | -$2.45 | -$2.92 | -$2.40 | -$1.64 | -$2.02 |
Income Statement Trend
Celldex Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 747.2M | 431.7M | 317.7M | 410.8M | 197.8M |
| Non-Current Assets | 45.2M | 33.9M | 35.0M | 33.8M | 38.0M |
| Total Assets | 792.3M | 465.6M | 352.7M | 444.7M | 235.8M |
| Liabilities | |||||
| Current Liabilities | 39.5M | 31.1M | 18.6M | 16.5M | 14.2M |
| Non-Current Liabilities | 5.8M | 5.3M | 7.9M | 8.6M | 12.3M |
| Total Liabilities | 45.3M | 36.5M | 26.5M | 25.2M | 26.5M |
| Equity | |||||
| Total Shareholders Equity | 747.0M | 429.2M | 326.2M | 419.5M | 209.4M |
Balance Sheet Composition
Celldex Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -157.9M | -141.4M | -112.3M | -70.5M | -59.8M |
| Operating Cash Flow | -133.8M | -116.4M | -98.1M | -63.0M | -58.9M |
| Investing Activities | |||||
| Capital Expenditures | -1.9M | -1.8M | -1.8M | -1.2M | -1.6M |
| Investing Cash Flow | -290.1M | -105.8M | 89.9M | -216.2M | -98.2M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 432.3M | 216.2M | 0 | 269.9M | 170.8M |
| Free Cash Flow | -159.7M | -109.1M | -105.6M | -62.2M | -42.0M |
Cash Flow Trend
Celldex Therapeutics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-9.17
Forward P/E
-6.61
Price to Book
2.02
Price to Sales
187.61
PEG Ratio
-6.61
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-9,027.19%
Return on Equity
-23.20%
Return on Assets
-16.88%
Financial Health
Current Ratio
21.67
Debt to Equity
0.49
Beta
1.14
Per Share Data
EPS (TTM)
-$2.70
Book Value per Share
$10.59
Revenue per Share
$0.11
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| cldx | 1.4B | -9.17 | 2.02 | -23.20% | 0.00% | 0.49 |
| Vertex | 124.2B | 32.82 | 7.53 | -5.64% | -8.91% | 10.00 |
| Regeneron | 59.1B | 13.92 | 1.97 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.6B | -8.85 | 2.90 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.7B | -33.90 | 4.41 | -5.86% | -6.48% | 114.67 |
| Agios | 2.1B | 3.17 | 1.44 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.